Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 30 June 2009
Vol. 2, Issue 77, p. ra31
[DOI: 10.1126/scisignal.2000352]
RESEARCH ARTICLES
Editor's Summary
Zooming In on ErbB3
Aberrant signaling involving the ErbB family of receptors, which can signal as homo- or heterodimers to activate the phosphatidylinositol 3-kinase (PI3K) signaling pathway, has been implicated as contributing to various cancers. Using a systems approach, Schoeberl et al. implicated ErbB3—a member of the ErbB family that is catalytically inactive—as critical to signaling stimulated by ligands that bind either ErbB1 or ErbB3. Computational analysis suggested that inhibiting ligand binding to ErbB3 might represent a more successful approach to treating cancers associated with ligand-induced stimulation of ErbB-PI3K signaling mediated by combinatorial receptor activation than do current therapies that target overexpressed or mutationally activated ErbB-family receptors. Moreover, experimental analysis revealed that a monoclonal antibody developed on the basis of this strategy could stop the growth of tumors grafted into immunodeficient mice.
Citation: B. Schoeberl, E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, V. Grantcharova, N. Kohli, K. A. West, M. Leszczyniecka, M. J. Feldhaus, A. J. Kudla, U. B. Nielsen, Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis. Sci. Signal.2, ra31 (2009).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORIAL GUIDES
Nancy R. Gough (6 September 2011) Sci. Signal.4 (189), eg8.
[DOI: 10.1126/scisignal.2002478] |Abstract »|Full Text »|PDF »
EDITORIAL GUIDES
Elizabeth M. Adler and Nancy R. Gough (29 March 2011) Sci. Signal.4 (166), eg3.
[DOI: 10.1126/scisignal.2002014] |Abstract »|Full Text »|PDF »
EDITORS' CHOICE
Nancy R. Gough (7 December 2010) Sci. Signal.3 (151), ec373.
[DOI: 10.1126/scisignal.3151ec373] |Abstract »
EDITORS' CHOICE
Nancy R. Gough (19 October 2010) Sci. Signal.3 (144), ec322.
[DOI: 10.1126/scisignal.3144ec322] |Abstract »
RESEARCH ARTICLES
Igor Astsaturov, Vladimir Ratushny, Anna Sukhanova, Margret B. Einarson, Tetyana Bagnyukova, Yan Zhou, Karthik Devarajan, Joshua S. Silverman, Nadezhda Tikhmyanova, Natalya Skobeleva, Anna Pecherskaya, Rochelle E. Nasto, Catherine Sharma, Sandra A. Jablonski, Ilya G. Serebriiskii, Louis M. Weiner, and Erica A. Golemis (21 September 2010) Sci. Signal.3 (140), ra67.
[DOI: 10.1126/scisignal.2001083] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
EDITORS' CHOICE
Annalisa M. VanHook (4 May 2010) Sci. Signal.3 (120), ec133.
[DOI: 10.1126/scisignal.3120ec133] |Abstract »
EDITORIAL GUIDES
Elizabeth M. Adler (5 January 2010) Sci. Signal.3 (103), eg1.
[DOI: 10.1126/scisignal.3103eg1] |Abstract »|Full Text »|PDF »
PODCASTS
Michael B. Yaffe and Annalisa M. VanHook (5 January 2010) Sci. Signal.3 (103), pc1.
[DOI: 10.1126/scisignal.3103pc1] |Abstract »|Full Text »|Podcast »
EDITORS' CHOICE
Nancy R. Gough (15 September 2009) Sci. Signal.2 (88), ec304.
[DOI: 10.1126/scisignal.288ec304] |Abstract »
PODCASTS
Ulrik B. Nielsen and Annalisa M. VanHook (30 June 2009) Sci. Signal.2 (77), pc12.
[DOI: 10.1126/scisignal.277pc12] |Abstract »|Full Text »|Podcast »
In Science Magazine
EDITORS' CHOICE: HIGHLIGHTS OF THE RECENT LITERATURE
L. Bryan Ray (24 July 2009) Science325 (5939), 369-b.
[DOI: 10.1126/science.325_369b] |Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Using Partial Least Squares Regression to Analyze Cellular Response Data.
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3.
C. F. McDonagh, A. Huhalov, B. D. Harms, S. Adams, V. Paragas, S. Oyama, B. Zhang, L. Luus, R. Overland, S. Nguyen, et al. (2012)
Mol. Cancer Ther.
11, 582-593
|Abstract »|Full Text »|PDF »
Reduction of Complex Signaling Networks to a Representative Kernel.
J.-R. Kim, J. Kim, Y.-K. Kwon, H.-Y. Lee, P. Heslop-Harrison, and K.-H. Cho (2011)
Science Signaling
4, ra35
|Abstract »|Full Text »|PDF »
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.
N. Kronqvist, M. Malm, L. Gostring, E. Gunneriusson, M. Nilsson, I. Hoiden Guthenberg, L. Gedda, F. Y. Frejd, S. Stahl, and J. Lofblom (2011)
Protein Eng. Des. Sel.
24, 385-396
|Abstract »|Full Text »|PDF »
Receptor Tyrosine Kinase Coactivation Networks in Cancer.
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation.
B. Schoeberl, A. C. Faber, D. Li, M.-C. Liang, K. Crosby, M. Onsum, O. Burenkova, E. Pace, Z. Walton, L. Nie, et al. (2010)
Cancer Res.
70, 2485-2494
|Abstract »|Full Text »|PDF »